Odomzo

Drug - Odomzo® (sonidegib) [Novartis]

March 2016

Therapeutic area - Basal cell carcinoma

Approval criteria

• Patient is 18 years of age or older AND
• Provider must:
  • Verify the pregnancy status of female patient OR
  • Advise the risk of exposure of male patient
• Patient has a diagnosis of basal cell carcinoma AND one of the following:
  • Disease has recurred after surgery or radiation OR
  • Patient is not a candidate for surgery or radiation

Quantity limit

Maximum of 34 capsules per 34 days

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411